Europe Breast Cancer Screening Tests Market Industry: Market Size & Forecast 2026

The European breast cancer screening market comprises a wide range of products and services, from digital mammography systems and MRI units to blood-based biomarkers and genetic tests, used primarily in organized population screening programs and clinical diagnostics. With a market value of roughly $1.33 billion in 2025, it represents a critical segment of the region's oncology diagnostics sector, supported by universal healthcare coverage and pan-European cancer control strategies. The market operates at the intersection of public health policy, reimbursement frameworks, and continuous medical technology innovation.

• •Digital mammography and tomosynthesis account for the largest share of screening test modalities in Europe.
• •National screening programs across EU member states typically target women aged 50 to 69 for routine biennial mammography.
• •In-vitro diagnostic tests, including liquid biopsies and molecular markers, are increasingly integrated with imaging workflows.

Europe's aging population and the corresponding rise in breast cancer incidence are primary catalysts for market expansion, as older women face statistically higher disease risk and require more frequent screening. Government-mandated screening programs, supported by Eurostat monitoring and EU health initiatives, ensure steady demand for diagnostic equipment and consumables across both Western and Eastern Europe. Additionally, the shift toward personalized medicine and value-based healthcare is prompting investments in high-sensitivity imaging and biomarker-based tests that promise earlier and more accurate detection.

• •The European Commission's Beating Cancer Plan and national cancer strategies continue to expand screening coverage and access.
• •Reimbursement incentives for digital breast tomosynthesis and contrast-enhanced mammography are boosting upgrade cycles.
• •Artificial intelligence algorithms for mammography reading are reducing radiologist workload and improving diagnostic accuracy.

The market is commonly segmented by product type into imaging systems (mammography, ultrasound, MRI), in-vitro diagnostic tests, and supporting digital infrastructure and software. Geographically, Western Europe, including Germany, France, the United Kingdom, and the Benelux countries, commands the largest share due to higher healthcare spending and earlier adoption of advanced technologies, while Eastern Europe is growing faster as screening programs expand and modernize. Within test categories, digital mammography dominates volume, while molecular diagnostics and next-generation sequencing are emerging as high-growth niche segments.

• •Germany, the UK, and France collectively represent over half of the European market by value.
• •Eastern European nations such as Poland and Hungary are expanding national screening programs with EU funding support.
• •Breast MRI and automated breast ultrasound are gaining share for high-risk patient screening.

What are the recent trends and outlook?

The market is moving toward AI-assisted screening, where machine learning algorithms support radiologists in reading mammograms and flagging suspicious findings, a shift expected to improve throughput and reduce observer variability. Personalized risk-based screening, using genetics, family history, and biomarkers to tailor intervals and modalities, is gaining traction as genomic testing costs decline. Looking ahead, the market is projected to maintain robust growth through 2030, with digital infrastructure upgrades, the rollout of 5G-connected imaging devices, and greater cross-border collaboration on cancer registries shaping the competitive environment.

• •AI-based computer-aided detection systems are being integrated into routine screening workflows in several EU countries.
• •Liquid biopsy and circulating tumor cell technologies are anticipated to enter routine screening protocols by the late 2020s.
• •Consolidation of screening services into regional hubs is driving demand for high-throughput imaging and PACS-integrated diagnostics.